Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2019; 10(12):2628-2634. doi:10.7150/jca.33117 This issue Cite

Research Paper

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2

Bo Li1, Dalong Xie2, Hui Zhang1✉

1. Department of Urinary surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China
2. Department of Anatomy, College of Basic Medicine, China Medical University, Shenyang, Liaoning, China

✉ Corresponding author: Hui Zhang, Department of Urinary surgery, Shengjing Hospital, China Medical University, No.36 Sanhao Street, Heping Area, Shenyang, 100004, China. Phone/Fax: +86-24-96615; E-mail address: zhangh10org

Citation:
Li B, Xie D, Zhang H. MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. J Cancer 2019; 10(12):2628-2634. doi:10.7150/jca.33117. https://www.jcancer.org/v10p2628.htm
Other styles

File import instruction

Abstract

Objective: Chemotherapy is a major therapeutic method for bladder urothelial carcinoma (BUC), which can effectively improve the prognosis of BUC patients, but the chemoresistance often leads to chemotherapy failure. This study will research the regulatory roles and molecular mechanism of miR-101-3p in BUC chemoresistance.

Materials and Methods: The quantitative real-time PCR was used to detect the expression of miRNA-101-3p and EZH2. The proliferation and chemoresistance were analyzed by CCK8 assay. Luciferase reporter assay was used to verify the combination between miR-101-3p and EZH2. Protein expression was detected by Western blotting. Flow cytometry was used to examine apoptosis rate.

Results: The miR-101-3p expression was down-regulated in cisplatin (CDDP) resistant BUC cell line (T24/CDDP) and tissues, and was positively related to sensitivity of BUC to CDDP. In T24/CDDP cells, the up-regulation of miR-101-3p decreased the half maximal inhibitory concentration (IC50) to CDDP, depressed the expression of MRP1 protein, promote the CDDP-induced cytotoxicity, and advanced CDDP sensitivity. A series of in vitro experiments certified the EZH2 gene was a target gene of miR-101-3p, including luciferase reporter assay, western blotting and so on. Up-regulation of EZH2 largely reversed the regulatory effects of miR-101-3p enhancement on CDDP sensitivity in T24/CDDP cells.

Conclusion: The expression of miR-101-3p is positively related to CDDP sensitivity of BUC, miR-101-3p advances sensitivity of BUC to CDDP through targeted silencing EZH2.

Keywords: bladder urothelial carcinoma, miR-101-3p, chemotherapy, cisplatin, EZH2

Citation styles

APA
Li, B., Xie, D., Zhang, H. (2019). MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. Journal of Cancer, 10(12), 2628-2634. https://doi.org/10.7150/jca.33117.

ACS
Li, B.; Xie, D.; Zhang, H. MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. J. Cancer 2019, 10 (12), 2628-2634. DOI: 10.7150/jca.33117.

NLM
Li B, Xie D, Zhang H. MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. J Cancer 2019; 10(12):2628-2634. doi:10.7150/jca.33117. https://www.jcancer.org/v10p2628.htm

CSE
Li B, Xie D, Zhang H. 2019. MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2. J Cancer. 10(12):2628-2634.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use